Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Dyserythropoiesis evaluated by RED score and hepcidin/ferritin levels predicts response to erythropoietin in lower risk myelodysplastic syndromes.

Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.

Haematologica. 2018 Oct 4. pii: haematol.2018.203158. doi: 10.3324/haematol.2018.203158. [Epub ahead of print]

2.

Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.

Garban F, Guyard A, Labussière H, Bulabois CE, Marchand T, Mounier C, Caillot D, Bay JO, Coiteux V, Schmidt-Tanguy A, Le Niger C, Robin C, Ladaique P, Lapusan S, Deconinck E, Rolland C, Foote AM, François A, Jacquot C, Tardivel R, Tiberghien P, Bosson JL; Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group.

JAMA Oncol. 2018 Apr 1;4(4):468-475. doi: 10.1001/jamaoncol.2017.5123.

PMID:
29392283
3.

[Non eligibility criteria for hematopoietic stem cell donors: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Boiron JM, Garban F, Audat F, Ader V, Andreu H, Aubrège-Bouvier C, Borel C, Huynh P, Nacimento F, Yakoub-Agha I, Chabannon C.

Bull Cancer. 2017 Dec;104(12S):S76-S83. doi: 10.1016/j.bulcan.2017.06.022. Epub 2017 Nov 22. French.

PMID:
29173975
4.

Targeted release of transcription factors for human cell reprogramming by ZEBRA cell-penetrating peptide.

Caulier B, Berthoin L, Coradin H, Garban F, Dagher MC, Polack B, Toussaint B, Lenormand JL, Laurin D.

Int J Pharm. 2017 Aug 30;529(1-2):65-74. doi: 10.1016/j.ijpharm.2017.06.073. Epub 2017 Jun 21.

PMID:
28647433
5.

Extracorporeal photopheresis for GVHD prophylaxis after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation: a prospective multicenter phase 2 study.

Michallet M, Sobh M, Garban F, Bulabois CE, Yakoub-Agha I, Coiteux V, Dulery R, Rohrlich PS, Legrand F, Clement L, Praire A, Detrait M, Barraco F, Nicolini FE, Hequet O.

Leuk Lymphoma. 2018 Feb;59(2):372-380. doi: 10.1080/10428194.2017.1334120. Epub 2017 Jun 7.

PMID:
28587506
6.

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.

Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A, Fegueux N, Tabrizi R, Finke J, El-Cheikh J, Schipperus M, Meijer E, von dem Borne P, Petersen E, Russell N, Tholouli E, Passweg J, Garban F, Maertens J, Chevalier P, Maillard N, Volin L, Francois S, Lioure B, Beguin Y, Gluckman E, Ruggeri A, Garderet L, Kröger N.

Haematologica. 2017 Jul;102(7):e271-e274. doi: 10.3324/haematol.2017.165399. Epub 2017 Apr 20. No abstract available.

7.

Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation.

Carré M, Thiebaut-Bertrand A, Larrat S, Leroy V, Pouzol P, Sturm N, Lhomme S, Cahn JY, Garban F, Morand P.

Bone Marrow Transplant. 2017 Apr;52(4):643-645. doi: 10.1038/bmt.2016.337. Epub 2017 Jan 9. No abstract available.

PMID:
28067868
8.

Targeted release of transcription factors for cell reprogramming by a natural micro-syringe.

Berthoin L, Toussaint B, Garban F, Le Gouellec A, Caulier B, Polack B, Laurin D.

Int J Pharm. 2016 Nov 20;513(1-2):678-687. doi: 10.1016/j.ijpharm.2016.09.081. Epub 2016 Sep 30.

PMID:
27697633
9.

High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Czerw T, Labopin M, Schmid C, Cornelissen JJ, Chevallier P, Blaise D, Kuball J, Vigouroux S, Garban F, Lioure B, Fegueux N, Clement L, Sandstedt A, Maertens J, Guillerm G, Bordessoule D, Mohty M, Nagler A.

Oncotarget. 2016 May 10;7(19):27255-66. doi: 10.18632/oncotarget.8463.

10.

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.

van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kötter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quéré I, Rich É, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socié G, Gratwohl A, Tyndall A; EBMT/EULAR Scleroderma Study Group.

JAMA. 2014 Jun 25;311(24):2490-8. doi: 10.1001/jama.2014.6368.

11.

Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease.

Meunier M, Bulabois CE, Thiebaut-Bertrand A, Itzykson R, Carre M, Carras S, Garban F, Cahn JY.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1451-4. doi: 10.1016/j.bbmt.2014.05.031. Epub 2014 Jun 6.

12.

Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Marcais A, Porcher R, Robin M, Mohty M, Michalet M, Blaise D, Tabrizi R, Clement L, Ceballos P, Daguindau E, Bilger K, Dhedin N, Lapusan S, Bay JO, Pautas C, Garban F, Ifrah N, Guillerm G, Contentin N, Bourhis JH, Yakoub Agha I, Bernard M, Cornillon J, Milpied N.

Haematologica. 2013 Sep;98(9):1467-75. doi: 10.3324/haematol.2012.080895. Epub 2013 Mar 28.

13.

Prophylactic platelet transfusions.

Pietersz RN, Reesink HW, Panzer S, Gilbertson MP, Borosak ME, Wood EM, Leitner GC, Rabitsch W, Ay C, Lambermont M, Deneys V, Sondag D, Compernolle V, Legrand D, François A, Tardivel R, Garban F, Sawant RB, Rebulla P, Handa M, Ohto H, Kerkhoffs JL, Brand A, Zhiburt E, Cid J, Escolar G, Lozano M, Puig L, Knutson F, Hallböök H, Lubenow N, Estcourt L, Stanworth S, Murphy MF, Williams L, Mraz DL, Ross RL, Snyder E.

Vox Sang. 2012 Aug;103(2):159-76. doi: 10.1111/j.1423-0410.2012.01595.x. Epub 2012 Apr 20. No abstract available.

PMID:
22519879
14.

Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia.

Garban F, Carras S, Drillat P, Jacob MC, Fabre B, Callanan M, Courby S, Makowski C, Cahn JY, Gressin R.

Ann Oncol. 2012 Sep;23(9):2386-90. doi: 10.1093/annonc/mds014. Epub 2012 Mar 15.

PMID:
22422944
15.

Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Fabre C, Koscielny S, Mohty M, Fegueux N, Blaise D, Maillard N, Tabrizi R, Michallet M, Socié G, Yakoub-Agha I, Garban F, Uzunov M, François S, Contentin N, Lapusan S, Bourhis JH.

Haematologica. 2012 Apr;97(4):482-90. doi: 10.3324/haematol.2011.049742. Epub 2011 Nov 4.

16.

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.

Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM).

Eur J Haematol. 2012 Mar;88(3):249-59. doi: 10.1111/j.1600-0609.2011.01729.x. Epub 2012 Jan 4.

PMID:
22023551
17.

Double reduced-intensity allogeneic hematopoietic stem cell transplantation: a retrospective study from the SFGM-TC.

Bay JO, Cabrespine A, Faucher C, Tabrizi R, Bordigoni P, Berceanu A, Coiteux V, Renaud M, Mialou V, Robin M, Kuentz M, Chevallier P, Dhédin N, Huynh A, Garban F, Witz F, Buzyn A, De Revel T, Galambrun C, Deconinck E, Contentin N, François S, Gratecos N, Blaise D, Michallet M; Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Biol Blood Marrow Transplant. 2012 Feb;18(2):250-6. doi: 10.1016/j.bbmt.2011.06.015. Epub 2011 Jul 13.

18.

Community-acquired invasive aspergillosis and outdoor filamentous fungal spore load: a relationship?

Brenier-Pinchart MP, Lebeau B, Borel JL, Quesada JL, Mallaret MR, Garban F, Brion JP, Molina L, Bosson JL, Thiebaut-Bertrand A, Grillot R, Pelloux H.

Clin Microbiol Infect. 2011 Sep;17(9):1387-90. doi: 10.1111/j.1469-0691.2011.03523.x. Epub 2011 Jul 11.

19.

Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007).

Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, Coignard B, Dromer F, Bretagne S; French Mycosis Study Group.

Clin Microbiol Infect. 2011 Dec;17(12):1882-9. doi: 10.1111/j.1469-0691.2011.03548.x. Epub 2011 Jun 10.

20.

A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.

Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, Escoffre-Barbe M, Legros L, Turlure P, Chevallier P, Larosa F, Garban F, Reman O, Rousselot P, Dhédin N, Delannoy A, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Haematologica. 2011 Feb;96(2):245-52. doi: 10.3324/haematol.2010.027862. Epub 2010 Oct 22.

Supplemental Content

Loading ...
Support Center